#BEGIN_DRUGCARD DB00653

# AHFS_Codes:
28:12.92
40:12.00
56:12.00
84:92.00
92:02.00*

# ATC_Codes:
A06AD04
A12CC02
B05XA05
D11AX05
V04CC02

# Absorption:
Not Available

# Biotransformation:
None

# Brand_Mixtures:
Acti Poultice (Eucalyptus Oil + Magnesium Sulfate + Menthol + Methyl Salicylate + Thymol)
Agobyl Granule (Magnesium Sulfate + Peptone)
Agobyl Liquide (Magnesium Sulfate + Peptone)
Alsilax (Boldo + Cascara Sagrada + Magnesium Sulfate + Pancreatin + Peptone)
Amino Acid Concentrate Inj (Arginine Hcl + Calcium Chloride + Dexpanthenol + Dextrose + Dl-Methionine + Glutamic Acid + Histidine Hcl + Isoleucine + L-Cysteine Hydrochloride + L-Lysine Hydrochloride + Leucine + Magnesium Sulfate + Nicotinamide + Phenylalanine + Potassium Chloride + Sodium Acetate + Threonine + Tryptophan + Valine + Vitamin B1 (Thiamine) + Vitamin B12 + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine))
Amino Acid Formula Inj (Alanine + Arginine + Calcium Chloride + Calcium D-Pantothenate + Dextrose + Dl-Methionine + Glutamic Acid + Glycine + Histidine + Isoleucine + L-Aspartic Acid + Leucine + Lysine + Magnesium Sulfate + Nicotinamide + Phenylalanine + Potassium Chloride + Proline + Pyridoxine Hydrochloride + Riboflavin 5'-Phosphate Sodium + Serine + Sodium Acetate + Sodium Glutamate + Thiamine Hydrochloride + Threonine + Tryptophan + Tyrosine + Valine + Vitamin B12)
Amino Acid Formula Inj (Alanine + Arginine + Calcium Chloride + Calcium D-Pantothenate + Dextrose + Glutamic Acid + Glycine + Histidine + Isoleucine + L-Aspartic Acid + Leucine + Lysine + Magnesium Sulfate + Methionine + Nicotinamide + Phenylalanine + Potassium Chloride + Proline + Pyridoxine Hydrochloride + Riboflavin-5-Phosphate + Serine + Sodium Acetate + Sodium Glutamate + Thiamine Hydrochloride + Threonine + Tryptophan + Tyrosine + Valine + Vitamin B12)
Amino Acid Inj (Arginine + Calcium Chloride + D-Pantothenic Acid (Calcium D-Pantothenate) + Dextrose + Histidine + Isoleucine + L-Cysteine Hydrochloride + Leucine + Lysine + Magnesium Sulfate + Methionine + Nicotinamide + Phenylalanine + Potassium Chloride + Pyridoxine Hydrochloride + Sodium Acetate + Threonine + Tryptophan + Valine + Vitamin B1 + Vitamin B12 + Vitamin B2)
Amino Lite (Arginine + Calcium Chloride + Dextrose + Isoleucine + L-Cysteine Hydrochloride + L-Histidine Hcl + L-Lysine Hydrochloride + Leucine + Magnesium Sulfate + Methionine + Nicotinic Acid + Phenylalanine + Potassium Chloride + Pyridoxine Hydrochloride + Sodium Glutamate + Thiamine Hydrochloride + Threonine + Tryptophan + Valine + Vitamin B12 + Vitamin B2 (Riboflavin 5'-Phosphate Sodium))
Amino Solution - Liq (Calcium Chloride + Calcium D-Pantothenate + Casein Hydrolysate + Dextrose + Magnesium Sulfate + Nicotinamide + Pyridoxine Hydrochloride + Sodium Acetate + Vitamin B1 (Acetiamine) + Vitamin B12 + Vitamin B2)
Amino Solution Inj (Arginine + Calcium Chloride + Calcium D-Pantothenate + Dextrose + Dl-Methionine + Histidine + Isoleucine + Leucine + Lysine + Magnesium Sulfate + Nicotinamide + Phenylalanine + Sodium Acetate + Threonine + Tryptophan + Valine + Vitamin B1 + Vitamin B12 + Vitamin B2 + Vitamin B6)
Anticoryzax (Calcium Lactophosphate + Magnesium Sulfate + Ribonucleic Acid + Vitamin C)
Bvs Amino Acid Solution Inj (Arginine Hcl + Calcium Chloride + Dexpanthenol + Dextrose + Dl-Isoleucine + L-Cysteine Hydrochloride + L-Histidine Hcl + L-Lysine Hydrochloride + Leucine + Magnesium Sulfate + Methionine + Nicotinamide + Phenylalanine + Potassium Chloride + Pyridoxine Hydrochloride + Sodium Acetate Hemodialysis + Sodium Glutamate + Threonine + Tryptophan + Valine + Vitamin B1 + Vitamin B12 + Vitamin B2)
Bylium Liq (Boldo + Cascara Sagrada + Magnesium Sulfate + Pancreatin + Peptone)
Calcium Lactate Et Magnesium Sulfate (Calcium Lactate + Magnesium Sulfate)
Calcium/Magnesium Drink (Calcium (Calcium Lactate, Calcium Carbonate, Calcium Glycerophosphate) + Magnesium (Magnesium Citrate, Magnesium Sulfate, Magnesium Oxide))
Calf Electrolytes (Calcium Lactate + Ferrous Sulfate + Magnesium Sulfate + Potassium Chloride + Sodium Chloride + Vitamin a + Vitamin B12)
Calf-Lyte (Calcium Chloride + Calcium D-Pantothenate + Dextrose + Glycine + Magnesium Sulfate + Potassium Chloride + Potassium Citrate + Potassium Phosphate Monobasic + Sodium Chloride + Sodium Phosphate Monobasic + Vitamin C)
Disc-Discovery Tablets (Calcium (Calcium Phosphate (Dibasic), Calcium Ascorbate) + Magnesium (Magnesium Sulfate, Magnesium Oxide) + Manganese (Manganese Sulfate) + Potassium (Potassium Citrate) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid, Calcium Ascorbate) + Vitamin D3 (Cholecalciferol) + Zinc Sulfate)
Eau Purgative Riga (Magnesium Sulfate + Sodium Sulfate)
Electrosul (Calcium Chloride + Calcium D-Pantothenate + Cobalt Sulfate + Copper Sulfate + Ferrous Sulfate + Magnesium Sulfate + Manganese Sulfate + Nicotinic Acid + Potassium Chloride + Sodium Chloride + Sulfamerazine Sodium + Sulfathiazole Sodium + Vitamin a + Vitamin B12 + Vitamin B2 + Vitamin D3 + Zinc Sulfate)
Flex Capsules (Calcium (Calcium Ascorbate) + Magnesium Sulfate + Potassium (Potassium Sulfate))
Formule 1705 - Liq (Magnesium Sulfate + Ox Bile Extract)
Ion Aid (Calcium Gluconate + Dextrose + Glycine + Magnesium Sulfate + Potassium Phosphate Monobasic + Sodium Chloride)
Laxabyl No109 (Barberry Root + Boldo + Cascara Sagrada + Magnesium Sulfate + Pancreatin + Peptone + Taraxacum Officinale Weber)
Life Guard H E Pws (Calcium Phosphate (Dibasic) + Dextrose + Glycine + Magnesium Sulfate + Potassium Chloride + Sodium Bicarbonate + Sodium Chloride)
Life Guard Oral (Calcium Phosphate (Dibasic) + Dextrose + Glycine + Magnesium Sulfate + Potassium Chloride + Protein + Sodium Bicarbonate + Sodium Chloride)
Life Guard Pws Twin-Pak (Calcium Phosphate + Dextrose + Glycine + Magnesium Sulfate + Potassium Chloride + Protein + Sodium Bicarbonate + Sodium Chloride)
Life-Guard H.E. Pwr (Calcium Phosphate + Dextrose + Glycine + Magnesium Sulfate + Potassium Chloride + Sodium Bicarbonate + Sodium Chloride)
Magnesium Cap (Magnesium Oxide + Magnesium Sulfate)
Magnesium Sulfate in 5%Dextrose Inj (20mg/Ml) (Dextrose + Magnesium Sulfate)
Medi-3-Sulvita (Calcium Chloride + D-Pantothenic Acid + Magnesium Sulfate + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sulfamerazine Sodium + Sulfamethazine Sodium + Sulfathiazole Sodium + Vitamin a + Vitamin B12 + Vitamin B2 + Vitamin D3)
Multi-Vi-Min Capsules (Biotin + Chromium (Chromium Hvp Chelate) + D-Pantothenic Acid (Calcium D-Pantothenate) + Folic Acid + Iron (Ferric Ammonium Citrate) + Magnesium Sulfate + Manganese (Manganese Oxide) + Molybdenum (Sodium Molybdate) + Nicotinamide + Potassium (Potassium Chloride) + Selenium (Sodium Selenite) + Vitamin a (Vitamin a Palmitate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B12 + Vitamin B2 (Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxal-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C + Vitamin E (Dl-Alpha Tocopheryl Acetate) + Zinc Sulfate)
Multiple Electrolyte Additive Inj (Calcium Gluconate + Magnesium Sulfate + Potassium Chloride + Sodium Chloride)
Multivitamins + Minerals - Tab (Biotin + Calcium D-Pantothenate + Calcium Phosphate (Dibasic) + Copper Sulfate + Dl-Alpha Tocopheryl Acetate + Ferrous Fumarate + Folic Acid + Magnesium Sulfate + Nicotinamide + Pyridoxine Hydrochloride + Thiamine Mononitrate + Vitamin a Palmitate + Vitamin B12 + Vitamin B2 + Vitamin C + Vitamin D3)
Multivitamins and Minerals (Biotin + Calcium (Calcium Phosphate) + Copper (Copper Sulfate) + D-Pantothenic Acid (Calcium D-Pantothenate) + Folic Acid + Iron + Magnesium Sulfate + Nicotinamide + Phosphorus (Calcium Phosphate) + Vitamin a (Vitamin a Palmitate) + Vitamin B1 (Thiamine Mononitrate) + Vitamin B12 + Vitamin B2 + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C + Vitamin D + Vitamin E (D-Alpha Tocopheryl Acetate))
Nutravit Pst (Calcium D-Pantothenate + Folic Acid + Iodine (Potassium Iodide) + Iron (Iron Peptonized) + Magnesium Sulfate + Manganese (Manganese Sulfate) + Nicotinamide + Pyridoxine Hydrochloride + Thiamine Hydrochloride + Vitamin a + Vitamin B12 + Vitamin B2 + Vitamin D + Vitamin E)
Poulti-Paste (Glycerine + Magnesium Sulfate + Methyl Salicylate)
Poultice (Acetic Acid + Glycerine + Kaolin + Magnesium Sulfate + Menthol + Sodium Borate)
Poultice - Pst (Acetic Acid + Kaolin + Magnesium Sulfate + Sodium Borate)
Poultice Powder (Aluminum Potassium Sulfate + Bentonite + Magnesium Sulfate + Methyl Salicylate)
Pro-Laxol Liq (Boldo + Cascara Sagrada + Magnesium Sulfate)
Pro-Lyte (Calcium Chloride + Calcium D-Pantothenate + Dextrose + Glycine + Magnesium Sulfate + Potassium Chloride + Potassium Citrate + Potassium Phosphate Monobasic + Sodium Chloride + Sodium Phosphate Monobasic + Vitamin C)
Ratanhia Comp. Drops (Calcium Fluoride + Esculin + Krameria (Triandra) + Magnesium Sulfate + Myrrh + Olea Europea Homeo Chemical + Silver Nitrate)
Reducine Medicated Poultice Pst (Aluminum Ammonium Sulfate Dodecahydrate + Bentonite + Glycerine + Kaolin + Magnesium Sulfate + Methyl Salicylate + Peppermint Oil)
Scarlet Pwr (Calcium Phosphate + Ethylenediamine Dihydroiodide + Fenugreek + Gentiana Lutea + Ginger + Iron Oxide + Linum Usitatissimum + Magnesium Carbonate + Magnesium Sulfate + Sodium Sulfate + Sodium Thiosulfate)
Solution Carda (Magnesium Sulfate + Potassium Bicarbonate + Sodium Bicarbonate)
Stress (Calcium Phosphate + Cobalt Sulfate + Copper Sulfate + Ferrous Gluconate + Magnesium Sulfate + Manganese Sulfate + Potassium Iodide + Sodium Phosphate Monobasic + Vitamin a + Vitamin D3 + Zinc Sulfate)
Stv Amino Acid Sol Inj (Arginine Hcl + Calcium Chloride + Dexpanthenol + Dextrose + Dl-Methionine + Glutamic Acid + Histidine Hcl + Isoleucine + L-Cysteine Hydrochloride + L-Lysine Hydrochloride + Leucine + Magnesium Sulfate + Nicotinamide + Phenylalanine + Potassium Chloride + Pyridoxine Hydrochloride + Sodium Acetate + Threonine + Tryptophan + Valine + Vitamin B1 (Thiamine) + Vitamin B12 + Vitamin B2 (Riboflavin))
Super Multiple Vitamins and Min Tab (Biotin + Calcium (Calcium Phosphate) + Calcium D-Pantothenate + Copper (Copper Sulfate) + D-Alpha Tocopheryl Acetate + Folic Acid + Iron + Magnesium Sulfate + Nicotinamide + Phosphorus (Calcium Phosphate) + Vitamin a (Vitamin a Palmitate) + Vitamin B1 (Thiamine Mononitrate) + Vitamin B12 + Vitamin B2 + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C + Vitamin D)
Tetra Fungistop (Magnesium Sulfate + Silver + Sodium Chloride)

# Brand_Names:
Not Available

# CAS_Registry_Number:
7487-88-9

# ChEBI_ID:
32599

# Chemical_Formula:
MgO4S

# Chemical_IUPAC_Name:
magnesium(2+) ion sulfate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
602264

# Description:
A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)

# Dosage_Forms:
Liquid	Intramuscular
Liquid	Intravenous
Liquid	Oral
Pellet	Oral
Powder	Oral
Solution	Intramuscular
Solution	Intravenous
Solution / drops	Oral

# Drug_Category:
Analgesics
Anesthetics
Anti-Arrhythmia Agents
Anticonvulsants
Calcium Channel Blockers
Tocolytic Agents

# Drug_Interactions:
Atazanavir	This gastric pH modifier decreases the levels/effects of atazanavir
Eltrombopag	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
Tiludronate	The divalent cation of oral Magnesium sulfate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours.
Triprolidine	The CNS depressants, Triprolidine and Magnesium sulfate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
Trovafloxacin	Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction.

# Drug_Reference:
16002955	Blitz M, Blitz S, Hughes R, Diner B, Beasley R, Knopp J, Rowe BH: Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest. 2005 Jul;128(1):337-44.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.91

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
710 mg/mL

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Magnesium Sulfate

# HET_ID:
Not Available

# Half_Life:
43.2 hours (for newborns)

# InChI_Identifier:
InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2

# InChI_Key:
InChIKey=CSNNHWWHGAXBCP-UHFFFAOYSA-L

# Indication:
Used for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D01108

# LIMS_Drug_ID:
653

# Mechanism_Of_Action:
Magnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Magnesium sulfate reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction. Additionally, Magnesium inhibits Ca<sup>2+</sup> influx through dihydropyridine-sensitive, voltage-dependent channels. This accounts for much of its relaxant action on vascular smooth muscle.

# Melting_Point:
1124 °C (decomposition)

# Molecular_Weight_Avg:
120.368

# Molecular_Weight_Mono:
119.936771076

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA450302

# Pharmacology:
Magnesium sulfate is a small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. Magnesium sulfate is gaining popularity as an initial treatment in the management of various dysrhythmias, particularly torsades de pointes, and dyrhythmias secondary to TCA overdose or digitalis toxicity.

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB00653

# Protein_Binding:
25-30%

# PubChem_Compound_ID:
24083

# PubChem_Substance_ID:
46508411

# RxList_Link:
http://www.rxlist.com/cgi/generic3/mgso4.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01080

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[Mg++].[O-]S([O-])(=O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Bitter salt
Magnesium Sulphate Hydrate
Magnesium sulfate anhydrous
Magnesium sulfate dried
Magnesium sulfate heptahydrate
Magnesium sulphate

# Synthesis_Reference:
Not Available

# Toxicity:
LD<sub>50</sub> = 1200 mg/kg (rat, subcutaneous). May be harmful if swallowed. May act as an irritant. Adverse reactions include hypotension, ECG changes, diarrhea, urinary retention, CNS depression and respiratory depression.

# Update_Date:
2013-02-08 16:19:31 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Magnesium_Sulfate

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CACNG1

# Drug_Target_1_GenBank_ID_Gene:
L07738

# Drug_Target_1_GenBank_ID_Protein:
306473

# Drug_Target_1_GeneCard_ID:
CACNG1

# Drug_Target_1_Gene_Name:
CACNG1

# Drug_Target_1_Gene_Sequence:
>669 bp
ATGTCCCAGACCAAAATGCTGAAGGTCCGCGTGACCCTCTTCTGCATCCTGGCAGGCATC
GTGCTGGCCATGACAGCCGTGGTAACCGACCACTGGGCTGTGCTGAGCCCCCACATGGAG
CACCACAACACTACCTGCGAGGCGGCCCACTTCGGCCTCTGGCGGATTTGTACCAAGCGC
ATCCCCATGGACGACAGCAAGACCTGCGGGCCCATCACCCTGCCCGGGGAGAAGAACTGT
TCCTACTTCAGGCATTTTAACCCCGGCGAGAGCTCGGAGATCTTCGAATTCACCACTCAG
AAGGAGTACAGCATCTCGGCAGCCGCCATCGCCATCTTCAGCCTTGGCTTCATCATCCTG
GGCAGCCTCTGTGTCCTCCTGTCCCTCGGGAAGAAGAGGGACTATCTGCTGCGACCCGCG
TCCATGTTCTATGCCTTTGCAGGTCTCTGCATCCTCGTCTCGGTGGAGGTCATGCGGCAG
TCGGTGAAGCGCATGATTGACAGTGAGGACACCGTCTGGATCGAGTACTATTACTCCTGG
TCCTTTGCCTGCGCCTGTGCCGCCTTCATCCTCCTCTTTCTCGGCGGTCTCGCCCTCCTG
CTGTTCTCCCTGCCTCGAATGCCCCGGAACCCATGGGAGTCCTGCATGGATGCTGAGCCC
GAGCACTAA

# Drug_Target_1_General_Function:
Involved in voltage-gated calcium channel activity

# Drug_Target_1_General_References:
8387489	Powers PA, Liu S, Hogan K, Gregg RG: Molecular characterization of the gene encoding the gamma subunit of the human skeletal muscle 1,4-dihydropyridine-sensitive Ca2+ channel (CACNLG), cDNA sequence, gene structure, and chromosomal location. J Biol Chem. 1993 May 5;268(13):9275-9.
8404045	Iles DE, Segers B, Weghuis DO, Suikerbuijk R, Wieringa B: Localization of the gamma-subunit of the skeletal muscle L-type voltage-dependent calcium channel gene (CACNLG) to human chromosome band 17q24 by in situ hybridization and identification of a polymorphic repetitive DNA sequence at the gene locus. Cytogenet Cell Genet. 1993;64(3-4):227-30.

# Drug_Target_1_HGNC_ID:
HGNC:1405

# Drug_Target_1_HPRD_ID:
00249

# Drug_Target_1_ID:
750

# Drug_Target_1_Locus:
17q24

# Drug_Target_1_Molecular_Weight:
25029

# Drug_Target_1_Name:
Voltage-dependent calcium channel gamma-1 subunit

# Drug_Target_1_Number_of_Residues:
222

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00822	PMP22_Claudin

# Drug_Target_1_Protein_Sequence:
>Voltage-dependent calcium channel gamma-1 subunit
MSQTKMLKVRVTLFCILAGIVLAMTAVVTDHWAVLSPHMEHHNTTCEAAHFGLWRICTKR
IPMDDSKTCGPITLPGEKNCSYFRHFNPGESSEIFEFTTQKEYSISAAAIAIFSLGFIIL
GSLCVLLSLGKKRDYLLRPASMFYAFAGLCILVSVEVMRQSVKRMIDSEDTVWIEYYYSW
SFACACAAFILLFLGGLALLLFSLPRMPRNPWESCMDAEPEH

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only as a multiple subunit complex

# Drug_Target_1_SwissProt_ID:
Q06432

# Drug_Target_1_SwissProt_Name:
CCG1_HUMAN

# Drug_Target_1_Synonyms:
Dihydropyridine- sensitive L-type, skeletal muscle calcium channel subunit gamma

# Drug_Target_1_Theoretical_pI:
7.10

# Drug_Target_1_Transmembrane_Regions:
11-29
105-129
140-155
180-204

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
CACNA2D1

# Drug_Target_2_GenBank_ID_Gene:
M76559

# Drug_Target_2_GenBank_ID_Protein:
179762

# Drug_Target_2_GeneCard_ID:
CACNA2D1

# Drug_Target_2_Gene_Name:
CACNA2D1

# Drug_Target_2_Gene_Sequence:
>3276 bp
ATGGCTGCTGGCTGCCTGCTGGCCTTGACTCTGACACTTTTCCAATCTTTGCTCATCGGC
CCCTCGTCGGAGGAGCCGTTCCCTTCGGCCGTCACTATCAAATCATGGGTGGATAAGATG
CAAGAAGACCTTGTCACACTGGCAAAAACAGCAAGTGGAGTCAATCAGCTTGTTGATATT
TATGAGAAATATCAAGATTTGTATACTGTGGAACCAAATAATGCACGCCAGCTGGTAGAA
ATTGCAGCCAGGGATATTGAGAAACTTCTGAGCAACAGATCTAAAGCCCTGGTGAGCCTG
GCATTGGAAGCGGAGAAAGTTCAAGCAGCTCACCAGTGGAGAGAAGATTTTGCAAGCAAT
GAAGTTGTCTACTACAATGCAAAGGATGATCTCGATCCTGAGAAAAATGACAGTGAGCCA
GGCAGCCAGAGGATAAAACCTGTTTTCATTGAAGATGCTAATTTTGGACGACAAATATCT
TATCAGCACGCAGCAGTCCATATTCCTACTGACATCTATGAGGGCTCAACAATTGTGTTA
AATGAACTCAACTGGACAAGTGCCTTAGATGAAGTTTTCAAAAAGAATCGCGAGGAAGAC
CCTTCATTATTGTGGCAGGTTTTTGGCAGTGCCACTGGCCTAGCTCGATATTATCCAGCT
TCACCATGGGTTGATAATAGTAGAACTCCAAATAAGATTGACCTTTATGATGTACGCAGA
AGACCATGGTACATCCAAGGAGCTGCATCTCCTAAAGACATGCTTATTCTGGTGGATGTG
AGTGGAAGTGTTAGTGGATTGACACTTAAACTGATCCGAACATCTGTCTCCGAAATGTTA
GAAACCCTCTCAGATGATGATTTCGTGAATGTAGCTTCATTTAACAGCAATGCTCAGGAT
GTAAGCTGTTTTCAGCACCTTGTCCAAGCAAATGTAAGAAATAAAAAAGTGTTGAAAGAC
GCGGTGAATAATATCACAGCCAAAGGAATTACAGATTATAAGAAGGGCTTTAGTTTTGCT
TTTGAACAGCTGCTTAATTATAATGTTTCCAGAGCAAACTGCAATAAGATTATTATGCTA
TTCACGGATGGAGGAGAAGAGAGAGCCCAGGAGATATTTAACAAATACAATAAAGATAAA
AAAGTACGTGTATTCAGGTTTTCAGTTGGTCAACACAATTATGAGAGAGGACCTATTCAG
TGGATGGCCTGTGAAAACAAAGGTTATTATTATGAAATTCCTTCCATTGGTGCAATAAGA
ATCAATACTCAGGAATATTTGGATGTTTTGGGAAGACCAATGGTTTTAGCAGGAGACAAA
GCTAAGCAAGTCCAATGGACAAATGTGTACCTGGATGCATTGGAACTGGGACTTGTCATT
ACTGGAACTCTTCCGGTCTTCAACATAACCGGCCAATTTGAAAATAAGACAAACTTAAAG
AACCAGCTGATTCTTGGTGTGATGGGAGTAGATGTGTCTTTGGAAGATATTAAAAGACTG
ACACCACGTTTTACACTGTGCCCCAATGGGTATTACTTTGCAATCGATCCTAATGGTTAT
GTTTTATTACATCCAAATCTTCAGCCAAAGAACCCCAAATCTCAGGAGCCAGTAACATTG
GATTTCCTTGATGCAGAGTTAGAGAATGATATTAAAGTGGAGATTCGAAATAAGATGATT
GATGGGGAAAGTGGAGAAAAAACATTCAGAACTCTGGTTAAATCTCAAGATGAGAGATAT
ATTGACAAAGGAAACAGGACATACACATGGACACCTGTCAATGGCACAGATTACAGTTTG
GCCTTGGTATTACCAACCTACAGTTTTTACTATATAAAAGCCAAACTAGAAGAGACAATA
ACTCAGGCCAGATCAAAAAAGGGCAAAATGAAGGATTCGGAAACCCTGAAGCCAGATAAT
TTTGAAGAATCTGGCTATACATTCATAGCACCAAGAGATTACTGCAATGACCTGAAAATA
TCGGATAATAACACTGAATTTCTTTTAAATTTCAACGAGTTTATTGATAGAAAAACTCCA
AACAACCCATCATGTAACGCGGATTTGATTAATAGAGTCTTGCTTGATGCAGGCTTTACA
AATGAACTTGTCCAAAATTACTGGAGTAAGCAGAAAAATATCAAGGGAGTGAAAGCACGA
TTTGTTGTGACTGATGGTGGGATTACCAGAGTTTATCCCAAAGAGGCTGGAGAAAATTGG
CAAGAAAACCCAGAGACATATGAGGACAGCTTCTATAAAAGGAGCCTAGATAATGATAAC
TATGTTTTCACTGCTCCCTACTTTAACAAAAGTGGACCTGGTGCCTATGAATCGGGCATT
ATGGTAAGCAAAGCTGTAGAAATATATATTCAAGGGAAACTTCTTAAACCTGCAGTTGTT
GGAATTAAAATTGATGTAAATTCCTGGATAGAGAATTTCACCAAAACCTCAATCAGAGAT
CCGTGTGCTGGTCCAGTTTGTGACTGCAAAAGAAACAGTGACGTAATGGATTGTGTGATT
CTGGATGATGGTGGGTTTCTTCTGATGGCAAATCATGATGATTATACTAATCAGATTGGA
AGATTTTTTGGAGAGATTGATCCCAGCTTGATGAGACACCTGGTTAATATATCAGTTTAT
GCTTTTAACAAATCTTATGATTATCAGTCAGTATGTGAGCCCGGTGCTGCACCAAAACAA
GGAGCAGGACATCGCTCAGCATATGTGCCATCAGTAGCAGACATATTACAAATTGGCTGG
TGGGCCACTGCTGCTGCCTGGTCTATTCTACAGCAGTTTCTCTTGAGTTTGACCTTTCCA
CGACTCCTTGAGGCAGTTGAGATGGAGGATGATGACTTCACGGCCTCCCTGTCCAAGCAG
AGCTGCATTACTGAACAAACCCAGTATTTCTTCGATAACGACAGTAAATCATTCAGTGGT
GTATTAGACTGTGGAAACTGTTCCAGAATCTTTCATGGAGAAAAGCTTATGAACACCAAC
TTAATATTCATAATGGTTGAGAGCAAAGGGACATGTCCATGTGACACACGACTGCTCATA
CAAGCGGAGCAGACTTCTGACGGTCCAAATCCTTGTGACATGGTTAAGCAACCTAGATAC
CGAAAAGGGCCTGATGTCTGCTTTGATAACAATGTCTTGGAGGATTATACTGACTGTGGT
GGTGTTTCTGGATTAAATCCCTCCCTGTGGTATATCATTGGAATCCAGTTTCTACTACTT
TGGCTGGTATCTGGCAGCACACACCGGCTGTTATGA

# Drug_Target_2_General_Function:
Cell motility

# Drug_Target_2_General_References:
1309651	Williams ME, Feldman DH, McCue AF, Brenner R, Velicelebi G, Ellis SB, Harpold MM: Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel human neuronal calcium channel subtype. Neuron. 1992 Jan;8(1):71-84.
16335952	Liu T, Qian WJ, Gritsenko MA, Camp DG 2nd, Monroe ME, Moore RJ, Smith RD: Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res. 2005 Nov-Dec;4(6):2070-80.

# Drug_Target_2_HGNC_ID:
HGNC:1399

# Drug_Target_2_HPRD_ID:
00245

# Drug_Target_2_ID:
762

# Drug_Target_2_Locus:
7q21-q22

# Drug_Target_2_Molecular_Weight:
123184

# Drug_Target_2_Name:
Voltage-dependent calcium channel subunit alpha-2/delta-1

# Drug_Target_2_Number_of_Residues:
1091

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00092	VWA
PF02743	Cache_1
PF08399	VWA_N
PF08473	VGCC_alpha2

# Drug_Target_2_Protein_Sequence:
>Voltage-dependent calcium channel subunit alpha-2/delta-1
MAAGCLLALTLTLFQSLLIGPSSEEPFPSAVTIKSWVDKMQEDLVTLAKTASGVNQLVDI
YEKYQDLYTVEPNNARQLVEIAARDIEKLLSNRSKALVSLALEAEKVQAAHQWREDFASN
EVVYYNAKDDLDPEKNDSEPGSQRIKPVFIEDANFGRQISYQHAAVHIPTDIYEGSTIVL
NELNWTSALDEVFKKNREEDPSLLWQVFGSATGLARYYPASPWVDNSRTPNKIDLYDVRR
RPWYIQGAASPKDMLILVDVSGSVSGLTLKLIRTSVSEMLETLSDDDFVNVASFNSNAQD
VSCFQHLVQANVRNKKVLKDAVNNITAKGITDYKKGFSFAFEQLLNYNVSRANCNKIIML
FTDGGEERAQEIFNKYNKDKKVRVFRFSVGQHNYERGPIQWMACENKGYYYEIPSIGAIR
INTQEYLDVLGRPMVLAGDKAKQVQWTNVYLDALELGLVITGTLPVFNITGQFENKTNLK
NQLILGVMGVDVSLEDIKRLTPRFTLCPNGYYFAIDPNGYVLLHPNLQPKNPKSQEPVTL
DFLDAELENDIKVEIRNKMIDGESGEKTFRTLVKSQDERYIDKGNRTYTWTPVNGTDYSL
ALVLPTYSFYYIKAKLEETITQARSKKGKMKDSETLKPDNFEESGYTFIAPRDYCNDLKI
SDNNTEFLLNFNEFIDRKTPNNPSCNADLINRVLLDAGFTNELVQNYWSKQKNIKGVKAR
FVVTDGGITRVYPKEAGENWQENPETYEDSFYKRSLDNDNYVFTAPYFNKSGPGAYESGI
MVSKAVEIYIQGKLLKPAVVGIKIDVNSWIENFTKTSIRDPCAGPVCDCKRNSDVMDCVI
LDDGGFLLMANHDDYTNQIGRFFGEIDPSLMRHLVNISVYAFNKSYDYQSVCEPGAAPKQ
GAGHRSAYVPSVADILQIGWWATAAAWSILQQFLLSLTFPRLLEAVEMEDDDFTASLSKQ
SCITEQTQYFFDNDSKSFSGVLDCGNCSRIFHGEKLMNTNLIFIMVESKGTCPCDTRLLI
QAEQTSDGPNPCDMVKQPRYRKGPDVCFDNNVLEDYTDCGGVSGLNPSLWYIIGIQFLLL
WLVSGSTHRLL

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-24

# Drug_Target_2_Specific_Function:
Calcium channel protein which plays an important role in excitation-contraction coupling

# Drug_Target_2_SwissProt_ID:
P54289

# Drug_Target_2_SwissProt_Name:
CA2D1_HUMAN

# Drug_Target_2_Synonyms:
Dihydropyridine-sensitive L-type calcium channel subunits alpha- 2/delta precursor

# Drug_Target_2_Theoretical_pI:
4.86

# Drug_Target_2_Transmembrane_Regions:
446-469906-9301067-1086

# Drug_Target_3_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
CACNA1C

# Drug_Target_3_GenBank_ID_Gene:
M92270

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
CACNA1C

# Drug_Target_3_Gene_Name:
CACNA1C

# Drug_Target_3_Gene_Sequence:
>6666 bp
ATGGTCAATGAGAATACGAGGATGTACATTCCAGAGGAAAACCACCAAGGTTCCAACTAT
GGGAGCCCACGCCCCGCCCATGCCAACATGAATGCCAATGCGGCAGCGGGGCTGGCCCCT
GAGCACATCCCCACCCCGGGGGCTGCCCTGTCGTGGCAGGCGGCCATCGACGCAGCCCGG
CAGGCTAAGCTGATGGGCAGCGCTGGCAATGCGACCATCTCCACAGTCAGCTCCACGCAG
CGGAAGCGGCAGCAATATGGGAAACCCAAGAAGCAGGGCAGCACCACGGCCACACGCCCG
CCCCGAGCCCTGCTCTGCCTGACCCTGAAGAACCCCATCCGGAGGGCCTGCATCAGCATT
GTCGAATGGAAACCATTTGAAATAATTATTTTACTGACTATTTTTGCCAATTGTGTGGCC
TTAGCGATCTATATTCCCTTTCCAGAAGATGATTCCAACGCCACCAATTCCAACCTGGAA
CGAGTGGAATATCTCTTTCTCATAATTTTTACGGTGGAAGCGTTTTTAAAAGTAATCGCC
TATGGACTCCTCTTTCACCCCAATGCCTACCTCCGCAACGGCTGGAACCTACTAGATTTT
ATAATTGTGGTTGTGGGGCTTTTTAGTGCAATTTTAGAACAAGCAACCAAAGCAGATGGG
GCAAACGCTCTCGGAGGGAAAGGGGCCGGATTTGATGTGAAGGCGCTGAGGGCCTTCCGC
GTGCTGCGCCCCCTGCGGCTGGTGTCCGGAGTCCCAAGTCTCCAGGTGGTCCTGAATTCC
ATCATCAAGGCCATGGTCCCCCTGCTGCACATCGCCCTGCTTGTGCTGTTTGTCATCATC
ATCTACGCCATCATCGGCTTGGAGCTCTTCATGGGGAAGATGCACAAGACCTGCTACAAC
CAGGAGGGCATAGCAGATGTTCCAGCAGAAGATGACCCTTCCCCTTGTGCGCTGGAAACG
GGCCACGGGCGGCAGTGCCAGAACGGCACGGTGTGCAAGCCCGGCTGGGATGGTCCCAAG
CACGGCATCACCAACTTTGACAACTTTGCCTTCGCCATGCTCACGGTGTTCCAGTGCATC
ACCATGGAGGGCTGGACGGACGTGCTGTACTGGGTCAATGATGCCGTAGGAAGGGACTGG
CCCTGGATCTATTTTGTTACACTAATCATCATAGGGTCATTTTTTGTACTTAACTTGGTT
CTCGGTGTGCTTAGCGGAGAGTTTTCCAAAGAGAGGGAGAAGGCCAAGGCCCGGGGAGAT
TTCCAGAAGCTGCGGGAGAAGCAGCAGCTAGAAGAGGATCTCAAAGGCTACCTGGATTGG
ATCACTCAGGCCGAAGACATCGATCCTGAGAATGAGGACGAAGGCATGGATGAGGAGAAG
CCCCGAAACATGAGCATGCCCACCAGTGAGACCGAGTCCGTCAACACCGAAAACGTGGCT
GGAGGTGACATCGAGGGAGAAAACTGCGGGGCCAGGCTGGCCCACCGGATCTCCAAGTCA
AAGTTCAGCCGCTACTGGCGCCGGTGGAATCGGTTCTGCAGAAGGAAGTGCCGCGCCGCA
GTCAAGTCTAATGTCTTCTACTGGCTGGTGATTTTCCTGGTGTTCCTCAACACGCTCACC
ATTGCCTCTGAGCACTACAACCAGCCCAACTGGCTCACAGAAGTCCAAGACACGGCAAAC
AAGGCCCTGCTGGCCCTGTTCACGGCAGAGATGCTCCTGAAGATGTACAGCCTGGGCCTG
CAGGCCTACTTCGTGTCCCTCTTCAACCGCTTTGACTGCTTCGTCGTGTGTGGCGGCATC
CTGGAGACCATCCTGGTGGAGACCAAGATCATGTCCCCACTGGGCATCTCCGTGCTCAGA
TGCGTCCGGCTGCTGAGGATTTTCAAGATCACGAGGTACTGGAACTCCTTGAGCAACCTG
GTGGCATCCTTGCTGAACTCTGTGCGCTCCATCGCCTCCCTGCTCCTTCTCCTCTTCCTC
TTCATCATCATCTTCTCCCTCCTGGGGATGCAGCTCTTTGGAGGAAAGTTCAACTTTGAT
GAGATGCAGACCCGGAGGAGCACATTCGATAACTTCCCCCAGTCCCTCCTCACTGTGTTT
CAGATCCTGACCGGGGAGGACTGGAATTCGGTGATGTATGATGGGATCATGGCTTATGGC
GGCCCCTCTTTTCCAGGGATGTTAGTCTGTATTTACTTCATCATCCTCTTCATCTGTGGA
AACTATATCCTACTGAATGTGTTCTTGGCCATTGCTGTGGACAACCTGGCTGATGCTGAG
AGCCTCACATCTGCCCAAAAGGAGGAGGAAGAGGAGAAGGAGAGAAAGAAGCTGGCCAGG
ACTGCCAGCCCAGAGAAGAAACAAGAGTTGGTGGAGAAGCCGGCAGTGGGGGAATCCAAG
GAGGAGAAGATTGAGCTGAAATCCATCACGGCTGACGGAGAGTCTCCACCCGCCACCAAG
ATCAACATGGATGACCTCCAGCCCAATGAAAATGAGGATAAGAGCCCCTACCCCAACCCA
GAAACTACAGGAGAAGAGGATGAGGAGGAGCCAGAGATGCCTGTCGGCCCTCGCCCACGA
CCACTCTCTGAGCTTCACCTTAAGGAAAAGGCAGTGCCCATGCCAGAAGCCAGCGCGTTT
TTCATCTTCAGCTCTAACAACAGGTTTCGCCTCCAGTGCCACCGCATTGTCAATGACACG
ATCTTCACCAACCTGATCCTCTTCTTCATTCTGCTCAGCAGCATTTCCCTGGCTGCTGAG
GACCCGGTCCAGCACACCTCCTTCAGGAACCATATTCTGTTTTATTTTGATATTGTTTTT
ACCACCATTTTCACCATTGAAATTGCTCTGAAGATCCTAGGCAATGCAGACTATGTCTTC
ACTAGTATCTTTACATTAGAAATTATCCTTAAGATGACTGCTTATGGGGCTTTCTTGCAC
AAGGGTTCTTTCTGCCGGAACTACTTCAACATCCTGGACCTGCTGGTGGTCAGCGTGTCC
CTCATCTCCTTTGGCATCCAGTCCAGTGCAATCAATGTCGTGAAGATCTTGCGAGTCCTG
CGAGTACTCAGGCCCCTGAGGGCCATCAACAGGGCCAAGGGGCTAAAGCATGTGGTTCAG
TGTGTGTTTGTCGCCATCCGGACCATCGGGAACATCGTGATTGTCACCACCCTGCTGCAG
TTCATGTTTGCCTGCATCGGGGTCCAGCTCTTCAAGGGAAAGCTGTACACCTGTTCAGAC
AGTTCCAAGCAGACAGAGGCGGAATGCAAGGGCAACTACATCACGTACAAAGACGGGGAG
GTTGACCACCCCATCATCCAACCCCGCAGCTGGGAGAACAGCAAGTTTGACTTTGACAAT
GTTCTGGCAGCCATGATGGCCCTCTTCACCGTCTCCACCTTCGAAGGGTGGCCAGAGCTG
CTGTACCGCTCCATCGACTCCCACACGGAAGACAAGGGCCCCATCTACAACTACCGTGTG
GAGATCTCCATCTTCTTCATCATCTACATCATCATCATCGCCTTCTTCATGATGAACATC
TTCGTGGGCTTCGTCATCGTCACCTTTCAGGAGCAGGGGGAGCAGGAGTACAAGAACTGT
GAGCTGGACAAGAACCAGCGACAGTGCGTGGAATACGCCCTCAAGGCCCGGCCCCTGCGG
AGGTACATCCCCAAGAACCAGCACCAGTACAAAGTGTGGTACGTGGTCAACTCCACCTAC
TTCGAGTACCTGATGTTCGTCCTCATCCTGCTCAACACCATCTGCCTGGCCATGCAGCAC
TACGGCCAGAGCTGCCTGTTCAAAATCGCCATGAACATCCTCAACATGCTCTTCACTGGC
CTCTTCACCGTGGAGATGATCCTGAAGCTCATTGCCTTCAAACCCAAGGGTTACTTTAGT
GATCCCTGGAATGTTTTTGACTTCCTCATCGTAATTGGCAGCATAATTGACGTCATTCTC
AGTGAGACTAATCACTATTTCTGTGATGCATGGAATACATTTGACGCCTTGATTGTTGTG
GGTAGCATTGTTGATATAGCAATCACCGAGGTAAACCCAGCTGAACATACCCAATGCTCT
CCCTCTATGAACGCAGAGGAAAACTCCCGCATCTCCATCACCTTCTTCCGCCTGTTCCGG
GTCATGCGTCTGGTGAAGCTGCTGAGCCGTGGGGAGGGCATCCGGACGCTGCTGTGGACC
TTCATCAAGTCCTTCCAGGCCCTGCCCTATGTGGCCCTCCTGATCGTGATGCTGTTCTTC
ATCTACGCGGTGATCGGGATGCAGGTGTTTGGGAAAATTGCCCTGAATGATACCACAGAG
ATCAACCGGAACAACAACTTTCAGACCTTCCCCCAGGCCGTGCTGCTCCTCTTCAGGTGT
GCCACCGGGGAGGCCTGGCAGGACATCATGCTGGCCTGCATGCCAGGCAAGAAGTGTGCC
CCAGAGTCCGAGCCCAGCAACAGCACGGAGGGTGAAACACCCTGTGGTAGCAGCTTTGCT
GTCTTCTACTTCATCAGCTTCTACATGCTCTGTGCCTTCCTGATCATCAACCTCTTTGTA
GCTGTCATCATGGACAACTTTGACTACCTGACAAGGGACTGGTCCATCCTTGGTCCCCAC
CACCTGGATGAGTTTAAAAGAATCTGGGCAGAGTATGACCCTGAAGCCAAGGGTCGTATC
AAACACCTGGATGTGGTGACCCTCCTCCGGCGGATTCAGCCGCCACTAGGTTTTGGGAAG
CTGTGCCCTCACCGCGTGGCTTGCAAACGCCTGGTCTCCATGAACATGCCTCTGAACAGC
GACGGGACAGTCATGTTCAATGCCACCCTGTTTGCCCTGGTCAGGACGGCCCTGAGGATC
AAAACAGAAGGGAACCTAGAACAAGCCAATGAGGAGCTGCGGGCGATCATCAAGAAGATC
TGGAAGCGGACCAGCATGAAGCTGCTGGACCAGGTGGTGCCCCCTGCAGGTGATGATGAG
GTCACCGTTGGCAAGTTCTACGCCACGTTCCTGATCCAGGAGTACTTCCGGAAGTTCAAG
AAGCGCAAAGAGCAGGGCCTTGTGGGCAAGCCCTCCCAGAGGAACGCGCTGTCTCTGCAG
GCTGGCTTGCGCACACTGCATGACATCGGGCCTGAGATCCGACGGGCCATCTCTGGAGAT
CTCACCGCTGAGGAGGAGCTGGACAAGGCCATGAAGGAGGCTGTGTCCGCTGCTTCTGAA
GATGACATCTTCAGGAGGGCCGGTGGCCTGTTCGGCAACCACGTCAGCTACTACCAAAGC
GACGGCCGGAGCGCCTTCCCCCAGACCTTCACCACTCAGCGCCCGCTGCACATCAACAAG
GCGGGCAGCAGCCAGGGCGACACTGAGTCGCCATCCCACGAGAAGCTGGTGGACTCCACC
TTCACCCCGAGCAGCTACTCGTCCACCGGCTCCAACGCCAACATCAACAACGCCAACAAC
ACCGCCCTGGGTCGCCTCCCTCGCCCCGCCGGCTACCCCAGCACGGTCAGCACTGTGGAG
GGCCACGGGCCCCCCTTGTCCCCTGCCATCCGGGTGCAGGAGGTGGCGTGGAAGCTCAGC
TCCAACAGGGAAAGGCACGTTCCGGTGTGTGAGGATCTGGAGCTCAGGAGGGATTCAGGC
TCAGCAGGGACTCAGGCTCACTGCCTTCTGCTCAGGAGAGCAAACCCCTCTAGGTGCCAC
TCCCGGGAGAGCCAGGCAGCCATGGCGGGTCAGGAGGAGACGTCTCAGGATGAGACCTAT
GAAGTGAAGATGAACCATGACACGGAGGCCTGCAGTGAGCCCAGCCTGCTCTCCACAGAG
ATGCTCTCCTACCAGGATGACGAAAATCGGCAACTGACGCTCCCAGAGGAGGACAAGAGG
GACATCCGGCAATCTCCGAAGAGGGGTTTCCTCCGCTCTGCCTCACTAGGTCGAAGGGCC
TCCTTCCACCTGGAATGTCTGAAGCGACAGAAGGACCGAGGGGGAGACATCTCTCAGAAG
ACAGTCCTGCCCTTGCATCTGGTTCATCATCAGGCATTGGCAGTGGCAGGCCTGAGCCCC
CTCCTCCAGAGAAGCCATTCCCCTGCCTCATTCCCTAGGCCTTTTGCCACCCCACCAGCC
ACACCTGGCAGCCGAGGCTGGCCCCCACAGCCCGTCCCCACCCTGCGGCTTGAGGGGGTC
GAGTCCAGTGAGAAACTCAACAGCAGCTTCCCATCCATCCACTGCGGCTCCTGGGCTGAG
ACCACCCCCGGTGGCGGGGGCAGCAGCGCCGCCCGGAGAGTCCGGCCCGTCTCCCTCATG
GTGCCCAGCCAGGCTGGGGCCCCAGGGAGGCAGTTCCACGGCAGTGCCAGCAGCCTGGTG
GAAGCGGTCTTGATTTCAGAAGGACTGGGGCAGTTTGCTCAAGATCCCAAGTTCATCGAG
GTCACCACCCAGGAGCTGGCCGACGCCTGCGACATGACCATAGAGGAGATGGAGAGCGCG
GCCGACAACATCCTCAGCGGGGGCGCCCCACAGAGCCCCAATGGCGCCCTCTTACCCTTT
GTGAACTGCAGGGACGCGGGGCAGGACCGAGCCGGGGGCGAAGAGGACGCGGGCTGTGTG
CGCGCGCGGGGTGGACCGAGTGAGGAGGAGCTCCAGGACAGCAGGGTCTACGTCAGCAGC
CTGTAG

# Drug_Target_3_General_Function:
Involved in voltage-gated calcium channel activity

# Drug_Target_3_General_References:
1316612	Soldatov NM: Molecular diversity of L-type Ca2+ channel transcripts in human fibroblasts. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4628-32.
1335957	Sun W, McPherson JD, Hoang DQ, Wasmuth JJ, Evans GA, Montal M: Mapping of a human brain voltage-gated calcium channel to human chromosome 12p13-pter. Genomics. 1992 Dec;14(4):1092-4.
1653763	Powers PA, Gregg RG, Lalley PA, Liao M, Hogan K: Assignment of the human gene for the alpha 1 subunit of the cardiac DHP-sensitive Ca2+ channel (CCHL1A1) to chromosome 12p12-pter. Genomics. 1991 Jul;10(3):835-9.
2173707	Perez-Reyes E, Wei XY, Castellano A, Birnbaumer L: Molecular diversity of L-type calcium channels. Evidence for alternative splicing of the transcripts of three non-allelic genes. J Biol Chem. 1990 Nov 25;265(33):20430-6.
7737988	Soldatov NM, Bouron A, Reuter H: Different voltage-dependent inhibition by dihydropyridines of human Ca2+ channel splice variants. J Biol Chem. 1995 May 5;270(18):10540-3.
7959794	Soldatov NM: Genomic structure of human L-type Ca2+ channel. Genomics. 1994 Jul 1;22(1):77-87.
8099908	Tang S, Mikala G, Bahinski A, Yatani A, Varadi G, Schwartz A: Molecular localization of ion selectivity sites within the pore of a human L-type cardiac calcium channel. J Biol Chem. 1993 Jun 25;268(18):13026-9.
8392192	Schultz D, Mikala G, Yatani A, Engle DB, Iles DE, Segers B, Sinke RJ, Weghuis DO, Klockner U, Wakamori M, et al.: Cloning, chromosomal localization, and functional expression of the alpha 1 subunit of the L-type voltage-dependent calcium channel from normal human heart. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6228-32.
9013606	Soldatov NM, Zuhlke RD, Bouron A, Reuter H: Molecular structures involved in L-type calcium channel inactivation. Role of the carboxyl-terminal region encoded by exons 40-42 in alpha1C subunit in the kinetics and Ca2+ dependence of inactivation. J Biol Chem. 1997 Feb 7;272(6):3560-6.
9087614	Klockner U, Mikala G, Eisfeld J, Iles DE, Strobeck M, Mershon JL, Schwartz A, Varadi G: Properties of three COOH-terminal splice variants of a human cardiac L-type Ca2+-channel alpha1-subunit. Am J Physiol. 1997 Mar;272(3 Pt 2):H1372-81.

# Drug_Target_3_HGNC_ID:
HGNC:1390

# Drug_Target_3_HPRD_ID:
00246

# Drug_Target_3_ID:
478

# Drug_Target_3_Locus:
12p13.3

# Drug_Target_3_Molecular_Weight:
248890

# Drug_Target_3_Name:
Voltage-dependent L-type calcium channel subunit alpha-1C

# Drug_Target_3_Number_of_Residues:
2221

# Drug_Target_3_PDB_ID:
1VYT

# Drug_Target_3_Pathway:
Acebutolol Pathway	SMP00296
Alprenolol Pathway	SMP00297
Amlodipine Pathway	SMP00376
Atenolol Pathway	SMP00298
Benazepril Pathway	SMP00145
Betaxolol Pathway	SMP00299
Bisoprolol Pathway	SMP00300
Captopril Pathway	SMP00146
Carvedilol Pathway	SMP00367
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Disopyramide Pathway	SMP00325
Enalapril Pathway	SMP00148
Esmolol Pathway	SMP00301
Felodipine Pathway	SMP00377
Flecainide Pathway	SMP00331
Fosinopril Pathway	SMP00149
Fosphenytoin (Antiarrhythmic) Pathway	SMP00326
Ibutilide Pathway	SMP00332
Isradipine Pathway	SMP00378
Labetalol Pathway	SMP00368
Lidocaine (Antiarrhythmic) Pathway	SMP00328
Lisinopril Pathway	SMP00150
Metoprolol Pathway	SMP00302
Mexiletine Pathway	SMP00329
Moexipril Pathway	SMP00151
Nadolol Pathway	SMP00303
Nebivolol Pathway	SMP00366
Nicotine Pathway	SMP00431
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Oxprenolol Pathway	SMP00304
Penbutolol Pathway	SMP00305
Perindopril Pathway	SMP00152
Phenytoin (Antiarrhythmic) Pathway	SMP00327
Pindolol Pathway	SMP00306
Procainamide (Antiarrhythmic) Pathway	SMP00324
Propranolol Pathway	SMP00307
Quinapril Pathway	SMP00153
Quinidine Pathway	SMP00323
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Tocainide Pathway	SMP00330
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_3_Pfam_Domain_Function:
PF00520	Ion_trans

# Drug_Target_3_Protein_Sequence:
>Voltage-dependent L-type calcium channel subunit alpha-1C
MVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAALSWQAAIDAAR
QAKLMGSAGNATISTVSSTQRKRQQYGKPKKQGSTTATRPPRALLCLTLKNPIRRACISI
VEWKPFEIIILLTIFANCVALAIYIPFPEDDSNATNSNLERVEYLFLIIFTVEAFLKVIA
YGLLFHPNAYLRNGWNLLDFIIVVVGLFSAILEQATKADGANALGGKGAGFDVKALRAFR
VLRPLRLVSGVPSLQVVLNSIIKAMVPLLHIALLVLFVIIIYAIIGLELFMGKMHKTCYN
QEGIADVPAEDDPSPCALETGHGRQCQNGTVCKPGWDGPKHGITNFDNFAFAMLTVFQCI
TMEGWTDVLYWVNDAVGRDWPWIYFVTLIIIGSFFVLNLVLGVLSGEFSKEREKAKARGD
FQKLREKQQLEEDLKGYLDWITQAEDIDPENEDEGMDEEKPRNMSMPTSETESVNTENVA
GGDIEGENCGARLAHRISKSKFSRYWRRWNRFCRRKCRAAVKSNVFYWLVIFLVFLNTLT
IASEHYNQPNWLTEVQDTANKALLALFTAEMLLKMYSLGLQAYFVSLFNRFDCFVVCGGI
LETILVETKIMSPLGISVLRCVRLLRIFKITRYWNSLSNLVASLLNSVRSIASLLLLLFL
FIIIFSLLGMQLFGGKFNFDEMQTRRSTFDNFPQSLLTVFQILTGEDWNSVMYDGIMAYG
GPSFPGMLVCIYFIILFICGNYILLNVFLAIAVDNLADAESLTSAQKEEEEEKERKKLAR
TASPEKKQELVEKPAVGESKEEKIELKSITADGESPPATKINMDDLQPNENEDKSPYPNP
ETTGEEDEEEPEMPVGPRPRPLSELHLKEKAVPMPEASAFFIFSSNNRFRLQCHRIVNDT
IFTNLILFFILLSSISLAAEDPVQHTSFRNHILFYFDIVFTTIFTIEIALKILGNADYVF
TSIFTLEIILKMTAYGAFLHKGSFCRNYFNILDLLVVSVSLISFGIQSSAINVVKILRVL
RVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIVIVTTLLQFMFACIGVQLFKGKLYTCSD
SSKQTEAECKGNYITYKDGEVDHPIIQPRSWENSKFDFDNVLAAMMALFTVSTFEGWPEL
LYRSIDSHTEDKGPIYNYRVEISIFFIIYIIIIAFFMMNIFVGFVIVTFQEQGEQEYKNC
ELDKNQRQCVEYALKARPLRRYIPKNQHQYKVWYVVNSTYFEYLMFVLILLNTICLAMQH
YGQSCLFKIAMNILNMLFTGLFTVEMILKLIAFKPKGYFSDPWNVFDFLIVIGSIIDVIL
SETNHYFCDAWNTFDALIVVGSIVDIAITEVNPAEHTQCSPSMNAEENSRISITFFRLFR
VMRLVKLLSRGEGIRTLLWTFIKSFQALPYVALLIVMLFFIYAVIGMQVFGKIALNDTTE
INRNNNFQTFPQAVLLLFRCATGEAWQDIMLACMPGKKCAPESEPSNSTEGETPCGSSFA
VFYFISFYMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWAEYDPEAKGRI
KHLDVVTLLRRIQPPLGFGKLCPHRVACKRLVSMNMPLNSDGTVMFNATLFALVRTALRI
KTEGNLEQANEELRAIIKKIWKRTSMKLLDQVVPPAGDDEVTVGKFYATFLIQEYFRKFK
KRKEQGLVGKPSQRNALSLQAGLRTLHDIGPEIRRAISGDLTAEEELDKAMKEAVSAASE
DDIFRRAGGLFGNHVSYYQSDGRSAFPQTFTTQRPLHINKAGSSQGDTESPSHEKLVDST
FTPSSYSSTGSNANINNANNTALGRLPRPAGYPSTVSTVEGHGPPLSPAIRVQEVAWKLS
SNRERHVPVCEDLELRRDSGSAGTQAHCLLLRRANPSRCHSRESQAAMAGQEETSQDETY
EVKMNHDTEACSEPSLLSTEMLSYQDDENRQLTLPEEDKRDIRQSPKRGFLRSASLGRRA
SFHLECLKRQKDRGGDISQKTVLPLHLVHHQALAVAGLSPLLQRSHSPASFPRPFATPPA
TPGSRGWPPQPVPTLRLEGVESSEKLNSSFPSIHCGSWAETTPGGGGSSAARRVRPVSLM
VPSQAGAPGRQFHGSASSLVEAVLISEGLGQFAQDPKFIEVTTQELADACDMTIEEMESA
ADNILSGGAPQSPNGALLPFVNCRDAGQDRAGGEEDAGCVRARGAPSEEELQDSRVYVSS
L

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the "high-voltage activated" (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin- GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing the alpha-1C subunit play an important role in excitation-contraction coupling in the heart. The various isoforms display marked differences in the sensitivity to DHP compounds

# Drug_Target_3_SwissProt_ID:
Q13936

# Drug_Target_3_SwissProt_Name:
CAC1C_HUMAN

# Drug_Target_3_Synonyms:
Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle
Voltage- gated calcium channel subunit alpha Cav1.2

# Drug_Target_3_Theoretical_pI:
6.70

# Drug_Target_3_Transmembrane_Regions:
125-143
161-181
194-212
233-251
271-290
381-405
525-543
559-578
587-605
616-634
654-673
729-753
901-919
936-955
988-1006
1014-1032
1052-1071
1162-1186
1240-1258
1274-1293
1302-1320
1373-1391
1411-1430
1500-1524

# Drug_Target_4_Cellular_Location:
Sarcolemma
cytoplasmic side
peripheral membrane protein
sarcolemmal membrane

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
CACNB1

# Drug_Target_4_GenBank_ID_Gene:
M92303

# Drug_Target_4_GenBank_ID_Protein:
179806

# Drug_Target_4_GeneCard_ID:
CACNB1

# Drug_Target_4_Gene_Name:
CACNB1

# Drug_Target_4_Gene_Sequence:
>1791 bp
ATGGTCCAGAAGACCAGCATGTCCCGGGGCCCTTACCCACCCTCCCAGGAGATCCCCATG
GAGGTCTTCGACCCCAGCCCGCAGGGCAAATACAGCAAGAGGAAAGGGCGATTCAAACGG
TCAGATGGGAGCACGTCCTCGGATACCACATCCAACAGCTTTGTCCGCCAGGGCTCAGCG
GAGTCCTACACCAGCCGTCCATCAGACTCTGATGTATCTCTGGAGGAGGACCGGGAAGCC
TTAAGGAAGGAAGCAGAGCGCCAGGCATTAGCGCAGCTCGAGAAGGCCAAGACCAAGCCA
GTGGCATTTGCTGTGCGGACAAATGTTGGCTACAATCCGTCTCCAGGGGATGAGGTGCCT
GTGCAGGGAGTGGCCATCACCTTCGAGCCCAAAGACTTCCTGCACATCAAGGAGAAATAC
AATAATGACTGGTGGATCGGGCGGCTGGTGAAGGAGGGCTGTGAGGTTGGCTTCATTCCC
AGCCCCGTCAAACTGGACAGCCTTCGCCTGCTGCAGGAACAGAAGCTGCGCCAGAACCGC
CTCGGCTCCAGCAAATCAGGCGATAACTCCAGTTCCAGTCTGGGAGATGTGGTGACTGGC
ACCCGCCGCCCCACACCCCCTGCCAGTGCCAAACAGAAGCAGAAGTCGACAGAGCATGTG
CCCCCCTATGACGTGGTGCCTTCCATGAGGCCCATCATCCTGGTGGGACCGTCGCTCAAG
GGCTACGAGGTTACAGACATGATGCAGAAAGCTTTATTTGACTTCTTGAAGCATCGGTTT
GATGGCAGGATCTCCATCACTCGTGTGACGGCAGATATTTCCCTGGCTAAGCGCTCAGTT
CTCAACAACCCCAGCAAACACATCATCATTGAGCGCTCCAACACACGCTCCAGCCTGGCT
GAGGTGCAGAGTGAAATCGAGCGAATCTTCGAGCTGGCCCGGACCCTTCAGTTGGTCGCT
CTGGATGCTGACACCATCAATCACCCAGCCCAGCTGTCCAAGACCTCGCTGGCCCCCATC
ATTGTTTACATCAAGATCACCTCTCCCAAGGTACTTCAAAGGCTCATCAAGTCCCGAGGA
AAGTCTCAGTCCAAACACCTCAATGTCCAAATAGCGGCCTCGGAAAAGCTGGCACAGTGC
CCCCCTGAAATGTTTGACATCATCCTGGATGAGAACCAATTGGAGGATGCCTGCGAGCAT
CTGGCGGAGTACTTGGAAGCCTATTGGAAGGCCACACACCCGCCCAGCAGCACGCCACCC
AATCCGCTGCTGAACCGCACCATGGCTACCGCAGCCCTGCGCCGTAGCCCTGCCCCTGTC
TCCAACCTCCAGGGACCCTACCTTGCTTCCGGGGACCAGCCACTGGAACGGGCCACCGGG
GAGCACGCCAGCATGCACGAGTACCCAGGGGAGCTGGGCCAGCCCCCAGGCCTTTACCCC
AGCAGCCACCCACCAGGCCGGGCAGGCACGCTACGGGCACTGTCCCGCCAAGACACTTTT
GATGCCGACACCCCCGGCAGCCGAAACTCTGCCTACACGGAGCTGGGAGACTCATGTGTG
GACATGGAGACTGACCCCTCAGAGGGCCCAGGGCTTGGAGACCCTGCAGGGGGCGCACCA
GCCCGACAGGGATCCTGGGAGGACGAGGAAGAAGACTATGAGGAAGAGCTGACCGACAAC
CGGAACCGGGGCCGGAATAAGGCCCGCTACTGGCCTGAGGGTGGGGGTCCAGTTTTGGGG
CGCAACAAGAATGAGCTGGAGGGCTGGGGACGAGGCGTCTACATTCGCTGA

# Drug_Target_4_General_Function:
Involved in voltage-gated calcium channel activity

# Drug_Target_4_General_References:
10624822	Hogan K, Greg RG, Powers PA: Structure and alternative splicing of the gene encoding the human beta1 subunit of voltage dependent calcium channels. Neurosci Lett. 1999 Dec 24;277(2):111-4.
1309651	Williams ME, Feldman DH, McCue AF, Brenner R, Velicelebi G, Ellis SB, Harpold MM: Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel human neuronal calcium channel subtype. Neuron. 1992 Jan;8(1):71-84.
1385409	Powers PA, Liu S, Hogan K, Gregg RG: Skeletal muscle and brain isoforms of a beta-subunit of human voltage-dependent calcium channels are encoded by a single gene. J Biol Chem. 1992 Nov 15;267(32):22967-72.
7916667	Collin T, Wang JJ, Nargeot J, Schwartz A: Molecular cloning of three isoforms of the L-type voltage-dependent calcium channel beta subunit from normal human heart. Circ Res. 1993 Jun;72(6):1337-44.
8395940	Iles DE, Segers B, Sengers RC, Monsieurs K, Heytens L, Halsall PJ, Hopkins PM, Ellis FR, Hall-Curran JL, Stewart AD, et al.: Genetic mapping of the beta 1- and gamma-subunits of the human skeletal muscle L-type voltage-dependent calcium channel on chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibility. Hum Mol Genet. 1993 Jul;2(7):863-8.
8905728	Fukuda K, Kaneko S, Yada N, Kikuwaka M, Akaike A, Satoh M: Cyclic AMP-dependent modulation of N- and Q-type Ca2+ channels expressed in Xenopus oocytes. Neurosci Lett. 1996 Oct 11;217(1):13-6.

# Drug_Target_4_HGNC_ID:
HGNC:1401

# Drug_Target_4_HPRD_ID:
11743

# Drug_Target_4_ID:
333

# Drug_Target_4_Locus:
17q21-q22

# Drug_Target_4_Molecular_Weight:
65714

# Drug_Target_4_Name:
Voltage-dependent L-type calcium channel subunit beta-1

# Drug_Target_4_Number_of_Residues:
598

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Acebutolol Pathway	SMP00296
Alfentanil Pathway	SMP00413
Alprenolol Pathway	SMP00297
Atenolol Pathway	SMP00298
Betaxolol Pathway	SMP00299
Bisoprolol Pathway	SMP00300
Carfentanil Pathway	SMP00414
Carvedilol Pathway	SMP00367
Codeine Pathway	SMP00405
Esmolol Pathway	SMP00301
Fentanyl Pathway	SMP00415
Glibenclamide Pathway	SMP00460
Gliclazide Pathway	SMP00461
Heroin Pathway	SMP00407
Hydrocodone Pathway	SMP00411
Hydromorphone Pathway	SMP00410
Labetalol Pathway	SMP00368
Methadone Pathway	SMP00408
Metoprolol Pathway	SMP00302
Morphine Pathway	SMP00406
Nadolol Pathway	SMP00303
Nateglinide Pathway	SMP00453
Nebivolol Pathway	SMP00366
Nicotine Pathway	SMP00431
Oxprenolol Pathway	SMP00304
Oxycodone Pathway	SMP00409
Oxymorphone Pathway	SMP00412
Penbutolol Pathway	SMP00305
Pindolol Pathway	SMP00306
Propranolol Pathway	SMP00307
Remifentanil Pathway	SMP00416
Repaglinide Pathway	SMP00454
Sufentanil Pathway	SMP00417

# Drug_Target_4_Pfam_Domain_Function:
PF00018	SH3_1
PF00774	Ca_channel_B

# Drug_Target_4_Protein_Sequence:
>Voltage-dependent L-type calcium channel subunit beta-1
MVQKTSMSRGPYPPSQEIPMEVFDPSPQGKYSKRKGRFKRSDGSTSSDTTSNSFVRQGSA
ESYTSRPSDSDVSLEEDREALRKEAERQALAQLEKAKTKPVAFAVRTNVGYNPSPGDEVP
VQGVAITFEPKDFLHIKEKYNNDWWIGRLVKEGCEVGFIPSPVKLDSLRLLQEQKLRQNR
LGSSKSGDNSSSSLGDVVTGTRRPTPPASAKQKQKSTEHVPPYDVVPSMRPIILVGPSLK
GYEVTDMMQKALFDFLKHRFDGRISITRVTADISLAKRSVLNNPSKHIIIERSNTRSSLA
EVQSEIERIFELARTLQLVALDADTINHPAQLSKTSLAPIIVYIKITSPKVLQRLIKSRG
KSQSKHLNVQIAASEKLAQCPPEMFDIILDENQLEDACEHLAEYLEAYWKATHPPSSTPP
NPLLNRTMATAALAASPAPVSNLQGPYLASGDQPLERATGEHASMHEYPGELGQPPGLYP
SSHPPGRAGTLRALSRQDTFDADTPGSRNSAYTELGDSCVDMETDPSEGPGLGDPAGGGT
PPARQGSWEDEEEDYEEELTDNRNRGRNKARYCAEGGGPVLGRNKNELEGWGRGVYIR

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting

# Drug_Target_4_SwissProt_ID:
Q02641

# Drug_Target_4_SwissProt_Name:
CACB1_HUMAN

# Drug_Target_4_Synonyms:
CAB1
Calcium channel voltage-dependent subunit beta 1

# Drug_Target_4_Theoretical_pI:
6.75

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cell membrane

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
CACNB2

# Drug_Target_5_GenBank_ID_Gene:
S60415

# Drug_Target_5_GenBank_ID_Protein:
300417

# Drug_Target_5_GeneCard_ID:
CACNB2

# Drug_Target_5_Gene_Name:
CACNB2

# Drug_Target_5_Gene_Sequence:
>1983 bp
ATGGTCCAAAGGGACATGTCCAAGTCGCCTCCCACAGCGGCGGCGGCGGTGGCGCAGGAG
ATCCAGATGGAACTGCTAGAGAACGTGGCTCCCGCGGGGGCGCTCGGAGCCGCCGCACAG
TCATATGGAAAAGGAGCCAGAAGGAAAAACAGATTTAAAGGATCTGATGGAAGCACGTCA
TCTGATACTACCTCAAATAGTTTTCTTCGCCAGGGTTCGGCAGACTCCTACACTAGCCGT
CCATCCGATTCCGATGTATCTCTGGAGGAGGACCGGGAGGCAGTGCGCAGAGAAGCGCAG
CAGGCCCAGGCACAGTTGGAAAAAGCAAAGACAAAGCCCGTTGCATTTGCGGTTCGGACA
GATGTCAGCTACAGTGCGGCCCATGAAGATGATGTTCCAGTGCCTGGCATGGCCATCTCA
TTCGAAGCAAAAGATTTTCTGCATGTTAAGGAAAAATTTAACAATGACTGGTGGATAGGG
CGATTGGTAAAAGAAGGCTGTGAAATCGGATTCATTCCAAGCCCAGTCAAACTAGAAAAC
ATGAGGCTGCAGCATGAACAGAGAGCCAAGCAAGGGAAATTCTACTCCAGTAAATCAGGA
GGAAATTCATCATCCAGTTTGGGTGACATAGTACCTAGTTCCAGAAAATCAACACCTCCA
TCATCTGCTATAGACATAGATGCTACTGGCTTAGATGCAGAAGAAAATGATATTCCAGCA
AACCACCGCTCCCCTAAACCCAGTGCAAACAGTGTAACGTCACCCCACTCCAAAGAGAAA
AGAATGCCCTTCTTTAAGAAGACAGAGCACACTCCTCCGTATGATGTGGTACCTTCCATG
CGACCAGTGGTCCTAGTGGGCCCTTCTCTGAAGGGCTACGAGGTCACAGATATGATGCAA
AAAGCGCTGTTTGATTTTTTAAAACACAGATTTGAAGGGCGGATATCCATCACAAGGGTC
ACCGCTGACATCTCGCTTGCCAAACGCTCGGTATTAAACAATCCCAGTAAGCACGCAATA
ATAGAAAGATCCAACACAAGGTCAAGCTTAGCGGAAGTTCAGAGTGAAATCGAAAGGATT
TTTGAAGTTGCAAGAACATTGCAGTTGGTGGTCCTTGACGCGGATACAATTAATCATCCA
GCTCAACTCAGTAAAACCTCCTTGGCCCCTATTATAGTATATGTAAAGATTTCTTCTCCT
AAGGTTTTACAAACCTTAATAAAATCTCGAGGGAAATCTCAAGCTAAACACCTCAACGTC
CAGATGGTAGCAGCTGATAAACTGGCTCAGTGTCCTCCAGAGCTGTTCGATGTGATCTTG
GATGAGAACCAGCTTGAGGATGCCTGTGAGCACCTTGCCGACTATCTGGAGGCCTACTGG
AAGGCCACCCATCCTCCCAGCAGTAGCCTCCCCAACCCTCTCCTTAGCCGTACATTAGCC
ACTTCAAGTCTGCCTCTTAGCCCCACCCTAGCCTCTAATTCACAGGGTTCTCAAGGTCAT
CAGAGGACTGATCGCTCCGCTCCTATCCGTTCTGCTTCCCAAGCTGAAGAAGAACCTAGT
GTGGAAGGAGTCAAGAAATCCCAGCACCGCTCTTCCTCCTCAGCCCCACACCACAACCAT
CGCAGTGGGACAAGTCGCGGCCTCTCCAGGCAAGAGACATTTGACTCGGAAACCCAGGAG
AGTCGAGACTCTGCCTACGTAGAGCCAAAGGAAGATTATTCCCATGACCACGTGGACCAC
TATGCCTCACACCGTGACCACAACCACAGAGACGAGACCCACGGGAGCAGTGACCACAGA
CACAGGGAGTCCCGGCACCGTTCCCGGGACGTGGATCGAGAGCAGGACCACAACGAGTGC
AACAAGCAGCAGCGCAGCCGTCATAAATCCAAGGATCGCTACTGTGAAAAGGATGGAGAA
GTGATATCAAAAAAACGGAATGAGGCTGGGGAGTGGAACAGGGATGTTTACATCCGCCAA
TGA

# Drug_Target_5_General_Function:
Not Available

# Drug_Target_5_General_References:
8494331	Rosenfeld MR, Wong E, Dalmau J, Manley G, Posner JB, Sher E, Furneaux HM: Cloning and characterization of a Lambert-Eaton myasthenic syndrome antigen. Ann Neurol. 1993 Jan;33(1):113-20.
9254841	Taviaux S, Williams ME, Harpold MM, Nargeot J, Lory P: Assignment of human genes for beta 2 and beta 4 subunits of voltage-dependent Ca2+ channels to chromosomes 10p12 and 2q22-q23. Hum Genet. 1997 Aug;100(2):151-4.

# Drug_Target_5_HGNC_ID:
HGNC:1402

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
4110

# Drug_Target_5_Locus:
10p12

# Drug_Target_5_Molecular_Weight:
73581

# Drug_Target_5_Name:
Voltage-dependent L-type calcium channel subunit beta-2

# Drug_Target_5_Number_of_Residues:
660

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Amlodipine Pathway	SMP00376
Benazepril Pathway	SMP00145
Captopril Pathway	SMP00146
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Disopyramide Pathway	SMP00325
Enalapril Pathway	SMP00148
Felodipine Pathway	SMP00377
Flecainide Pathway	SMP00331
Fosinopril Pathway	SMP00149
Fosphenytoin (Antiarrhythmic) Pathway	SMP00326
Ibutilide Pathway	SMP00332
Isradipine Pathway	SMP00378
Lidocaine (Antiarrhythmic) Pathway	SMP00328
Lisinopril Pathway	SMP00150
Mexiletine Pathway	SMP00329
Moexipril Pathway	SMP00151
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Perindopril Pathway	SMP00152
Phenytoin (Antiarrhythmic) Pathway	SMP00327
Procainamide (Antiarrhythmic) Pathway	SMP00324
Quinapril Pathway	SMP00153
Quinidine Pathway	SMP00323
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Tocainide Pathway	SMP00330
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_5_Pfam_Domain_Function:
PF00018	SH3_1
PF00774	Ca_channel_B

# Drug_Target_5_Protein_Sequence:
>Voltage-dependent L-type calcium channel subunit beta-2
MVQRDMSKSPPTAAAAVAQEIQMELLENVAPAGALGAAAQSYGKGARRKNRFKGSDGSTS
SDTTSNSFVRQGSADSYTSRPSDSDVSLEEDREAVRREAERQAQAQLEKAKTKPVAFAVR
TNVSYSAAHEDDVPVPGMAISFEAKDFLHVKEKFNNDWWIGRLVKEGCEIGFIPSPVKLE
NMRLQHEQRAKQGKFYSSKSGGNSSSSLGDIVPSSRKSTPPSSAIDIDATGLDAEENDIP
ANHRSPKPSANSVTSPHSKEKRMPFFKKTEHTPPYDVVPSMRPVVLVGPSLKGYEVTDMM
QKALFDFLKHRFEGRISITRVTADISLAKRSVLNNPSKHAIIERSNTRSSLAEVQSEIER
IFELARTLQLVVLDADTINHPAQLSKTSLAPIIVYVKISSPKVLQRLIKSRGKSQAKHLN
VQMVAADKLAQCPPELFDVILDENQLEDACEHLADYLEAYWKATHPPSSSLPNPLLSRTL
ATSSLPLSPTLASNSQGSQGDQRTDRSAPIRSASQAEEEPSVEPVKKSQHRSSSSAPHHN
HRSGTSRGLSRQETFDSETQESRDSAYVEPKEDYSHDHVDHYASHRDHNHRDETHGSSDH
RHRESRHRSRDVDREQDHNECNKQRSRHKSKDRYCEKDGEVISKKRNEAGEWNRDVYIRQ

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting

# Drug_Target_5_SwissProt_ID:
Q08289

# Drug_Target_5_SwissProt_Name:
CACB2_HUMAN

# Drug_Target_5_Synonyms:
CAB2
Calcium channel voltage-dependent subunit beta 2
Lambert-Eaton myasthenic syndrome antigen B
MYSB

# Drug_Target_5_Theoretical_pI:
8.26

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Membrane

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
CACNA1S

# Drug_Target_6_GenBank_ID_Gene:
U30707

# Drug_Target_6_GenBank_ID_Protein:
1698403

# Drug_Target_6_GeneCard_ID:
CACNA1S

# Drug_Target_6_Gene_Name:
CACNA1S

# Drug_Target_6_Gene_Sequence:
>5616 bp
ATGGAGCCATCCTCACCCCAGGATGAAGGCCTGAGGAAGAAACAGCCCAAGAAGCCAGTT
CCTGAGATTCTGCCAAGCCCACCCCGGGCCTTGTTCTGCCTGACCCTGGAGAACCCCCTG
AGGAAGGCCTGCATCAGCATTGTAGAATGGAAGCCCTTCGAGACGATCATCTTGCTCACC
ATCTTTGCCAATTGTGTGGCCCTGGCCGTGTACCTGCCCATGCCGGAAGATGACAACAAC
TCTCTGAACCTCGGCCTGGAGAAGCTGGAGTATTTCTTCCTCATTGTCTTCTCGATTGAA
GCCGCCATGAAGATCATTGCCTACGGCTTCTTATTCCACCAGGACGCTTACCTGCGCAGT
GGCTGGAATGTGCTGGACTTCACCATTGTCTTCCTGGGGGTCTTCACCGTGATTCTGGAA
CAGGTTAACGTCATCCAAAGCCACACAGCCCCAATGAGCAGCAAAGGAGCCGGCTTGGAT
GTCAAGGCCCTCAGAGCCTTCCGAGTGCTCAGACCCCTCCGGCTGGTGTCGGGGGTGCCT
AGCCTGCAGGTGGTCCTGAACTCCATCTTCAAGGCCATGCTCCCCCTCTTTCACATCGCC
CTGCTGGTCCTCTTTATGGTCATCATCTATGCCATCATCGGGCTGGAGCTCTTCAAGGGC
AAGATGCACAAGACCTGCTACTTCATTGGTACAGATATCGTGGCCACGGTGGAGAATGAA
GAGCCATCGCCCTGCGCCAGGACGGGCTCAGGGCGCCGGTGCACCATCAATGGCAGTGAG
TGCCGGGGCGGCTGCCCAGGGCCCAACCATGGCATCACCCACTTCGACAACTTCGGCTTC
TCCATGCTCACCGTGTACCAGTGCATTACCATGGAGGGATGGACTGACGTCCTTTACTGG
GTCAATGATGCCATCGGGAATGAGTGGCCCTGGATCTATTTTGTCACCCTCATTTTGCTG
GGATCCTTCTTCATCCTCAACCTGGTGCTGGGTGTCCTGAGTGGGGAATTCACCAAGGAG
CGGGAGAAGGCCAAGTCCAGGGGAACCTTCCAGAAGCTCCGGGAGAAGCAGCAACTAGAT
GAGGACCTTCGGGGCTACATGAGCTGGATCACGCAGGGCGAGGTCATGGATGTTGAGGAC
TTCAGAGAAGGAAAACTGTCTTTGGATGAAGGTGGCTCTGACACAGAGAGCCTGTATGAA
ATTGCAGGCTTGAACAAAATCATCCAGTTCATCCGACATTGGAGGCAGTGGAACCGCATC
TTTCGCTGGAAGTGCCATGACATCGTGAAGTCCAAGGTCTTCTATTGGCTGGTGATTCTC
ATCGTTGCCCTCAACACCCTGTCTATCGCCTCAGAGCACCACAACCAGCCTCTCTGGCTG
ACCCGTTTGCAAGACATTGCCAACCGGGTGCTGCTGTCCCTCTTCACCACTGAGATGCTG
ATGAAGATGTACGGGCTGGGCCTGCGCCAGTACTTCATGTCTATCTTCAACCGCTTCGAC
TGCTTCGTGGTGTGCAGCGGTATCCTGGAGATCCTGCTGGTGGAGTCGGGCGCCATGACA
CCCCTGGGCATCTCCGTGCTCCGCTGCATCCGCCTCCTGAGGATCTTCAAGATCACCAAA
TATTGGACGTCGCTGAGCAACCTGGTGGCATCCCTGCTCAACTCCATCCGCTCCATCGCC
TCCCTGCTGCTGCTGCTCTTCCTCTTCATCGTCATCTTCCGCCTCCTGGGCATGCAGCTC
TTTGGGGGGAGGTATGACTTTGAAGACACAGAAGTACGGCGCAGCAACTTTGACAACTTT
CCCCAAGCCCTCATCAGCGTCTTCCAGGTACTGACAGGGGAAGACTGGACCTCAATGATG
TACAATGGGATCATGGCCTACCGGGGCCCGTCCTACCCTGGCATGCTTGTGTGCATTTAC
TTCATCATCCTTTTCGTCTGTGGCAACTACATCCTGCTCAATGTCTTCCTGGCCATTGCC
GTGGACAACCTGGCCGAGGCGGAGAGCCTGACTTCTGCCCAGAAGGCCAAGGCTGAGGAG
AAAAAACGCAGGAAGATGTCCAAGGGTCTCCCAGACAAGTCAGAAGAGGAGAAGTCAACG
ATGGCCAAGAAGCTGGAGCAGAAACCCAAGGGTGAGGGCATCCCCACCACTGCCAAGCTG
AAAATCGATGAGTTTGAATCTAATGTCAATGAGGTGAAGGATCCCTACCCCTCAGCCGAC
TTCCCAGGGGATGACGAGGAAGATGAGCCTGAGATCCCGCTGAGCCCCCGACCACGTCCC
CTGGCTGAGCTGCAGCTGAAAGAGAAGGCCGTGCCCATTCCAGAAGCCAGCTCCTTCTTC
ATCTTCAGCCCCACCAATAAGATCCGTGTCCTGTGTCACCGCATCGTCAATGCCACCTGG
TTTACCAACTTCATCCTGCTCTTCATCCTGCTCAGCAGCGCTGCACTGGCTGCGGAAGAC
CCCATCCGGGCTGATTCCATGAGAAATCAGATCCTTAAACACTTTGACATCGGGTTCACC
TCTGTCTTCACTGTGGAGATTGTCCTCAAGATGACGACCTACGGAGCCTTCCTGCACAAG
GGTTCCTTCTGCCGCAATTACTTCAACATGCTGGACCTGCTGGTGGTGGCCGTGTCCCTC
ATCTCCATGGGACTTGAGTCCAGTGCCATCTCCGTGGTGAAGATCCTGAGGGTGCTGAGG
GTGCTCCGACCACTCAGAGCCATCAACAGAGCCAAGGGGTTGAAGTGCATGTTCGTGGCC
ATCAGCACCATCGGGAACATCGTGCTGGTCACTACCCTCCTACAGTTCATGTTTGCCTGC
ATCGGCGTCCAGCTCTTCAAGGGGAAGTTCTTCAGGTGCACCGACTTGTCCAAGATGACA
GAGGAGGAGTGCAGGGGCTACTACTACGTGTACAAGGACGGGGACCCCATGCAGATAGAG
CTGCGTCACCGCGAGTGGGTACACAGCGACTTCCACTTCGACAATGTGCTCTCAGCCATG
ATGTCCCTCTTCACGGTCTCCACCTTCGAGGGATGGCCTCAGCTGCTGTACAAGGCCATA
GACTCCAATGCGGAGGACGTGGGTCCCATCTACAACAACCGTGTGGAGATGGCCATCTTC
TTCATCATCTACATCATCCTCATTGCCTTCTTCATGATGAACATCTTTGTGGGCTTCGTC
ATTGTCACCTTCCAGGAGCAGGGAGAGACTGAGTACAAGAACTGTGAGCTGGACAAGAAC
CAGCGCCAATGTGTACAGTATGCCCTGAAGGCCCGCCCACTGAGGTGCTACATTCCCAAA
AACCCATACCAGTACCAGGTGTGGTACATTGTCACCTCCTCCTACTTTGAATACCTGATG
TTTGCCCTCATCATGCTCAACACCATCTGCCTCGGCATGCAGCACTACAACCAGTCGGAG
CAGATGAACCACATCTCAGACATCCTCAATGTGGCCTTCACTATCATCTTCACCCTGGAG
ATGATCCTCAAGCTCATGGCCTTCAAGGCCAGGGGCTACTTTGGAAACCCCTGGAATGTG
TTTGACTTCCTGATTGTCATTGGCAGCATCATTGATGTCATCCTCAGTGAGATCGACACT
TTCCTGGCCTCCAGCGGGGGACTGTATTGCCTGGGTGGAGGCTGCGGGAACGTTGACCCA
GATGAGAGTGCCCGCATCTCCAGCGCCTTCTTCCGCCTGTTCCGTGTCATGAGGCTGATC
AAGCTGCTGAGCCGGGCAGAAGGAGTGCGAACCCTCCTGTGGACGTTCATCAAGTCCTTC
CAGGCCCTACCCTACGTGGCTCTGCTCATCGTCATGCTCTTCTTCATCTACGCTGTCATC
GGCATGCAGATGTTTGGGAAGATCGCCTTGGTGGATGGGACCCAAATAAACCGGAACAAC
AACTTCCAGACCTTCCCACAAGCAGTGCTACTGCTCTTCAGGCACGCGTGTGCAACAGGT
GAGGCCTGGCAGGAGATCCTACTGGCCTGCAGCTATGGGAAGCTGTGTGACCCAGAGTCG
GACTATGCCCCAGGGGAGGAGTACACATGTGGCACCAACTTTGCATACTACTACTTCATC
AGCTTCTACATGCTCTGTGCCTTCCTGGTCATCAACCTCTTTGTGGCTGTCATCATGGAC
AATTTTGACTACCTCACCCGGGACTGGTCCATCCTGGGCCCTCATCACCTGGATGAGTTC
AAGGCCATCTGGGCAGAGTATGACCCAGAGGCTAAGGGGAGAATCAAACACCTGGACGTG
GTGACCCTGCTGAGAAGGATTCAGCCCCCTCTGGGCTTTGGGAAGTTCTGCCCACATCGG
GTAGCTTGTAAGCGGCTGGTGGGCATGAACATGCCCCTGAACAGCGACGGCACAGTCACC
TTCAATGCCACACTCTTTGCCCTGGTCGGCACGGCACTCAAGATCAAGACGGAAGGTAAC
TTTGAGCAGGCCAACGAGGAGCTGAGGGCCATCATCAAGAAGATCTGGAAGAGAACCAGC
ATGAAGCTCTTGGACCAGGTCATGCCTCCAATAGGAGATGATGAGGTGACAGTGGGGAAG
TTCTACGCCACATTCCTGATCCAGGAGGACTTCCGGAAGTTCATGAAACGCCAAGAGGAG
TATTATGGCTATCGGCCCAAGAAGGACATTGTACAGATCCAGGCAGGGCTGCGGACCATT
GAGGAAGAGGCAGCCCCCGAGATCTGTCGCACGGTCTCAGGAGACCTGGCTGCTGAGGAG
GAGCTGGAGAGAGCCATGGTGGAGGCTGCGATGGAGGAGGGAATATTCCGGAGGACTGGA
GGCCTGTTTGGCCAGGTGGACAACTTCCTGGAAAGGACCAACTCCCTGCCCCCTGTCATG
GCCAATCAGAGACCCCTCCAGTTTGCTGAGATAGAGATGGAAGAGATGGAGTCACCTGTC
TTCTTGGAGGACTTCCCACAAGATCCACGCACCAACCCCCTGGCTCGTGCCAATACCAAC
AATGCCAACGCCAATGTCGCCTATGCGAACAGCAACCATAGCAACAGCCATGTGTTTTCC
AGTGTCCACTATGAAAGGGAGTTCCCAGAAGAGACAGAGACGCCTGCTACCAGAGGACGA
GCCCTTGGCCAACCCTGCAGGGTCCTGGGACCCCACAGCAAACCCTGTGTGGAGATGCTG
AAGGGACTGCTGACCCAGAGGGCAATGCCCAGAGGCCAGGCACCTCCTGCCCCCTGCCAG
TGCCCCAGGGTGGAGTCCTCCATGCCTGAGGACAGAAAGAGCTCCACACCAGGGTCTCTT
CATGAGGAGACACCCCACAGCAGGAGCACCAGGGAGAATACTTCCAGGTGCTCAGCACCA
GCTACAGCCCTGCTGATCCAAAAGGCTCTGGTTCGAGGGGGCCTGGGCACCTTGGCAGCT
GATGCAAACTTCATCATGGCAACAGGCCAGGCCCTCGGAGATGCCTGCCAAATGGAACCA
GAGGAAGTGGAGATCATGGCAACAGAGCTACTGAAAGGACGAGAGGCCCCAGACGGCATG
GCCAGCTCCCTGGGATGCCTGAACCTCGGGTCCTCCCTGGGCAGCCTCGACCAACACCAG
GGCTCCCAGGAGACCCTTATTCCTCCAAGGCTGTGA

# Drug_Target_6_General_Function:
Not Available

# Drug_Target_6_General_References:
7713519	Hogan K, Powers PA, Gregg RG: Cloning of the human skeletal muscle alpha 1 subunit of the dihydropyridine-sensitive L-type calcium channel (CACNL1A3). Genomics. 1994 Dec;24(3):608-9.
7916735	Gregg RG, Couch F, Hogan K, Powers PA: Assignment of the human gene for the alpha 1 subunit of the skeletal muscle DHP-sensitive Ca2+ channel (CACNL1A3) to chromosome 1q31-q32. Genomics. 1993 Jan;15(1):107-12.
7987325	Jurkat-Rott K, Lehmann-Horn F, Elbaz A, Heine R, Gregg RG, Hogan K, Powers PA, Lapie P, Vale-Santos JE, Weissenbach J, et al.: A calcium channel mutation causing hypokalemic periodic paralysis. Hum Mol Genet. 1994 Aug;3(8):1415-9.
8004673	Ptacek LJ, Tawil R, Griggs RC, Engel AG, Layzer RB, Kwiecinski H, McManis PG, Santiago L, Moore M, Fouad G, et al.: Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell. 1994 Jun 17;77(6):863-8.
8838325	Hogan K, Gregg RG, Powers PA: The structure of the gene encoding the human skeletal muscle alpha 1 subunit of the dihydropyridine-sensitive L-type calcium channel (CACNL1A3). Genomics. 1996 Feb 1;31(3):392-4.
9199552	Monnier N, Procaccio V, Stieglitz P, Lunardi J: Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet. 1997 Jun;60(6):1316-25.

# Drug_Target_6_HGNC_ID:
HGNC:1397

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
4111

# Drug_Target_6_Locus:
1q32

# Drug_Target_6_Molecular_Weight:
212167

# Drug_Target_6_Name:
Voltage-dependent L-type calcium channel subunit alpha-1S

# Drug_Target_6_Number_of_Residues:
1873

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00520	Ion_trans
PF08763	Ca_chan_IQ

# Drug_Target_6_Protein_Sequence:
>Voltage-dependent L-type calcium channel subunit alpha-1S
MEPSSPQDEGLRKKQPKKPVPEILPSPPRALFCLTLENPLRKACISIVEWKPFETIILLT
IFANCVALAVYLPMPEDDNNSLNLGLEKLEYFFLIVFSIEAAMKIIAYGFLFHQDAYLRS
GWNVLDFTIVFLGVFTVILEQVNVIQSHTAPMSSKGAGLDVKALRAFRVLRPLRLVSGVP
SLQVVLNSIFKAMLPLFHIALLVLFMVIIYAIIGLELFKGKMHKTCYFIGTDIVATVENE
EPSPCARTGSGRRCTINGSECRGGWPGPNHGITHFDNFGFSMLTVYQCITMEGWTDVLYW
VNDAIGNEWPWIYFVTLILLGSFFILNLVLGVLSGEFTKEREKAKSRGTFQKLREKQQLD
EDLRGYMSWITQGEVMDVEDFREGKLSLDEGGSDTESLYEIAGLNKIIQFIRHWRQWNRI
FRWKCHDIVKSKVFYWLVILIVALNTLSIASEHHNQPLWLTRLQDIANRVLLSLFTTEML
MKMYGLGLRQYFMSIFNRFDCFVVCSGILEILLVESGAMTPLGISVLRCIRLLRIFKITK
YWTSLSNLVASLLNSIRSIASLLLLLFLFIVIFALLGMQLFGGRYDFEDTEVRRSNFDNF
PQALISVFQVLTGEDWTSMMYNGIMAYGGPSYPGMLVCIYFIILFVCGNYILLNVFLAIA
VDNLAEAESLTSAQKAKAEEKKRRKMSKGLPDKSEEEKSTMAKKLEQKPKGEGIPTTAKL
KIDEFESNVNEVKDPYPSADFPGDDEEDEPEIPLSPRPRPLAELQLKEKAVPIPEASSFF
IFSPTNKIRVLCHRIVNATWFTNFILLFILLSSAALAAEDPIRADSMRNQILKHFDIGFT
SVFTVEIVLKMTTYGAFLHKGSFCRNYFNMLDLLVVAVSLISMGLESSAISVVKILRVLR
VLRPLRAINRAKGLKHVVQCMFVAISTIGNIVLVTTLLQFMFACIGVQLFKGKFFRCTDL
SKMTEEECRGYYYVYKDGDPMQIELRHREWVHSDFHFDNVLSAMMSLFTVSTFEGWPQLL
YKAIDSNAEDVGPIYNNRVEMAIFFIIYIILIAFFMMNIFVGFVIVTFQEQGETEYKNCE
LDKNQRQCVQYALKARPLRCYIPKNPYQYQVWYIVTSSYFEYLMFALIMLNTICLGMQHY
NQSEQMNHISDILNVAFTIIFTLEMILKLMAFKARGYFGDPWNVFDFLIVIGSIIDVILS
EIDTFLASSGGLYCLGGGCGNVDPDESARISSAFFRLFRVMRLIKLLSRAEGVRTLLWTF
IKSFQALPYVALLIVMLFFIYAVIGMQMFGKIALVDGTQINRNNNFQTFPQAVLLLFRCA
TGEAWQEILLACSYGKLCDPESDYAPGEEYTCGTNFAYYYFISFYMLCAFLVINLFVAVI
MDNFDYLTRDWSILGPHHLDEFKAIWAEYDPEAKGRIKHLDVVTLLRRIQPPLGFGKFCP
HRVACKRLVGMNMPLNSDGTVTFNATLFALVGTALKIKTEGNFEQANEELRAIIKKIWKR
TSMKLLDQVMPPIGDDEVTVGKFYATFLIQEDFRKFMKRQEEYYGYRPKKDIVQIQAGLR
TIEEEAAPEICRTVSGDLAAEEELERAMVEAAMEEGIFRRTGGLFGQVDNFLERTNSLPP
VMANQRPLQFAEIEMEEMESPVFLEDFPQDPRTNPLARANTNNANANVAYGNSNHSNSHV
FSSVHYEREFPEETETPATRGRALGQPCRVLGPHSKPCVEMLKGLLTQRAMPRGQAPPAP
CQCPRVESSMPEDRKSSTPGSLHEETPHSRSTRENTSRCSAPATALLIQKALVRGGLGTL
AADANFIMATGQALGDACQMEPEEVEIMATELLKGREAPEGMASSLGCLNLGSSLGSLDQ
HQGSQETLIPPRL

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the "high-voltage activated" (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin- GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing the alpha-1S subunit play an important role in excitation-contraction coupling in skeletal muscle

# Drug_Target_6_SwissProt_ID:
Q13698

# Drug_Target_6_SwissProt_Name:
CAC1S_HUMAN

# Drug_Target_6_Synonyms:
Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle
Voltage- gated calcium channel subunit alpha Cav1.1

# Drug_Target_6_Theoretical_pI:
6.36

# Drug_Target_6_Transmembrane_Regions:
52-70
89-108
121-139
161-179
199-218
310-334
433-451
467-486
495-513
524-542
562-581
637-661
800-818
835-854
867-885
893-911
931-950
1041-1065
1119-1137
1153-1172
1181-1199
1232-1250
1270-1289
1357-1381

#END_DRUGCARD DB00653
